Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
BCE
BCE
$21.8B
| $92.2M | 0.12% |
2,046,571
-112,800
| -5% | -$5.08M |
|
|
MZTI
202
The Marzetti Company
MZTI
$3.15B
| $92.1M | 0.12% |
750,762
+140,262
| +23% | +$17.6M |
|
203
Ross Stores
ROST
$80.8B
| $90.8M | 0.12% |
1,573,128
+1,254,028
| +393% | +$78.3M |
|
|
WCN
204
Waste Connections
WCN
$42B
| $90.3M | 0.12% |
1,401,211
+208,550
| +17% | +$13M |
|
205
PLDT
PHI
$4.23B
| $89.8M | 0.11% |
2,543,600
-71,200
| -3% | -$2.51M |
|
|
LOGM
206
DELISTED
LogMein, Inc.
LOGM
| $88.8M | 0.11% |
849,869
-170,273
| -17% | -$18.6M |
|
207
Alcoa
AA
$14.3B
| $88.8M | 0.11% |
2,719,496
-784,500
| -22% | -$25.5M |
|
208
Stellantis
STLA
$20.5B
| $88.4M | 0.11% |
8,353,380
+4,528,582
| +118% | +$48.2M |
|
|
SNI
209
DELISTED
Scripps Networks Interactive, Inc Common Class A
SNI
| $88.3M | 0.11% |
1,293,300
+979,500
| +312% | +$69M |
|
210
OraSure Technologies
OSUR
$268M
| $88.1M | 0.11% |
5,103,903
-28,100
| -0.5% | -$405K |
|
211
Toronto Dominion Bank
TD
$201B
| $88.1M | 0.11% |
1,748,075
-40,225
| -2% | -$1.94M |
|
212
Commault Systems
CVLT
$5.78B
| $87.8M | 0.11% |
1,555,213
+377,313
| +32% | +$20.6M |
|
|
MGLN
213
DELISTED
Magellan Health Services, Inc.
MGLN
| $87.4M | 0.11% |
1,198,799
-14,300
| -1% | -$1M |
|
214
PVH
PVH
$3.91B
| $87.2M | 0.11% |
761,670
+461,600
| +154% | +$47.9M |
|
215
CenterPoint Energy
CNP
$26.5B
| $87.1M | 0.11% |
3,182,200
-165,300
| -5% | -$4.64M |
|
|
FNSR
216
DELISTED
Finisar Corp
FNSR
| $87.1M | 0.11% |
3,351,600
-935,400
| -22% | -$23.3M |
|
217
Royal Caribbean
RCL
$82.1B
| $86.9M | 0.11% |
795,400
+368,200
| +86% | +$39.1M |
|
218
Digital Realty Trust
DLR
$70.6B
| $86.8M | 0.11% |
768,100
+371,000
| +93% | +$42.5M |
|
219
Synchrony
SYF
$25.5B
| $86.6M | 0.11% |
2,904,800
-194,900
| -6% | -$5.78M |
|
220
Thomson Reuters
TRI
$45.4B
| $86M | 0.11% |
1,600,086
+288,410
| +22% | +$14.8M |
|
221
Apple
AAPL
$4.45T
| $84.2M | 0.11% |
+2,337,732
| New | +$86.4M |
|
|
ZNGA
222
DELISTED
ZYNGA INC. CL A COMMON
ZNGA
| $83.8M | 0.11% |
23,009,600
+5,759,000
| +33% | +$18.9M |
|
|
PPLI
223
People Inc
PPLI
$2.97B
| $82.8M | 0.11% |
4,487,668
+3,509,999
| +359% | +$59.6M |
|
224
Cogent Communications
CCOI
$554M
| $82.5M | 0.11% |
2,058,600
+245,100
| +14% | +$10.2M |
|
225
PACCAR
PCAR
$69.8B
| $82.3M | 0.11% |
+1,869,267
| New | +$80.8M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.